In Brief: Beconase
This article was originally published in The Tan Sheet
Executive Summary
Beconase: FDA advisory committee's Oct. 10-11 consideration of Schering- Plough's Rx rhinitis switch candidate Vancenase AQ (beclomethasone dipropionate) will not include review of Glaxo Wellcome's identical Rx product, Beconase. Glaxo Wellcome has not filed a switch NDA for Beconase as yet, the company said. Dosage for OTC Vancenase AQ would be the same as the prescription product. The Nonprescription Drug and Pulmonary Allergy Drug Advisory Committees also will review McNeil's proposed switch of Nasalcrom (cromolyn sodium) at the meeting ("The Tan Sheet" Sept. 9, p. 1)...